Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Annals of Surgical Oncology
Erschienen in: Annals of Surgical Oncology 4/2009

01.04.2009 | Gastrointestinal Oncology

Response to Preoperative Therapy in Upper Gastrointestinal Cancers

verfasst von: Björn L. D. M. Brücher, MD, PhD, FACS, Stephen G. Swisher, MD, FACS, Alfred Königsrainer, MD, Derek Zieker, MD, Jörg Hartmann, MD, Hubert Stein, MD, Yuko Kitagawa, MD, FACS, Simon Law, MD, FACS, FRCS, Jaffer A. Ajani, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 4/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

In cancer, a response to therapy implies a reduction in the volume or activity of localized and/or metastatic tumors. In localized upper gastrointestinal cancer, there is no accepted definition of clinical response; however, tumor shrinkage is frequently observed when preoperative therapy is administered. As patients with upper gastrointestinal cancers often undergo multimodal therapy, it is therefore imperative that new definitions for assessing the response to preoperative therapy be established.

Methods

We reviewed the development of response criteria from a historical perspective, with particular emphasis on the criteria used to assess upper gastrointestinal cancers.

Results

Observing the response to preoperative therapy appears to make it possible to distinguish between favorable and unfavorable clinical biology in the cancer. Patients who experience a response to preoperative treatment appear to fare better in terms of overall survival than those whose cancers do not respond. We reviewed the published results regarding the response to preoperative therapy and the implications of this for patients.

Conclusions

This review of the literature suggests that a variety of tools are available for defining the response to preoperative therapy and that these need to be exploited. Developing reliable methods of assessing the response will improve the individualization of therapy for patients with gastroesophageal cancer. There is a strong need for surrogate markers for efficacy in order to assess responses that are capable of predicting patient outcome.
Literatur
1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin. 2005;55(1):10–30.PubMedCrossRef
2.
Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26(5 Suppl 15):2–8.PubMed
3.
van Blankenstein M, Looman CW, Hop WC, Bytzer P. The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett’s esophagus makes a difference. Am J Gastroenterol. 2005;100(4):766–74.PubMedCrossRef
4.
Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005;97(2):142–6.PubMedCrossRef
5.
Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.PubMedCrossRef
6.
Brücher BLDM, Stein HJ, Werner M, Siewert JR. Lymphatic vessel invasion is an independent prognostic factor in patients with a primary resected tumor with esophageal squamous cell carcinoma. Cancer. 2001;92(8):2228–33.PubMedCrossRef
7.
Stein HJ, von Rahden BH, Siewert JR. Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch Surg. 2005;390(4):280–5.PubMedCrossRef
8.
Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, et al. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2004;60(2):427–36.PubMed
9.
Ilson DH. Oesophageal cancer: new developments in systemic therapy. Cancer Treat Rev. 2003;29(6):525–32.PubMedCrossRef
10.
Greil R, Stein HJ. Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer? Lancet Oncol. 2007;8(3):189–90.PubMedCrossRef
11.
Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23(10):2310–7.PubMedCrossRef
12.
Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D et al. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337(3):161–7.PubMedCrossRef
13.
Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P et al. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659–68.PubMedCrossRef
14.
Le Prise E, Etienne PL, Meunier B, Maddern G, Ben Hassel M, Gedouin D et al. A randomized study of chemotherapy, radiation therapy, and surgery versus surgery for localized squamous cell carcinoma of the esophagus. Cancer. 1994;73(7):1779–84.PubMedCrossRef
15.
Nygaard K, Hagen S, Hansen HS, Hatlevoll R, Hultborn R, Jakobsen A et al. Pre-operative radiotherapy prolongs survival in operable esophageal carcinoma: a randomized, multicenter study of pre-operative radiotherapy and chemotherapy The second Scandinavian trial in esophageal cancer. World J Surg. 1992;16(6):1104–9 (discussion 1110).PubMedCrossRef
16.
Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305–13.PubMed
17.
Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462–7 (see comments) (published erratum appears in N Engl J Med. 1999 Jul 29;341(5):384).
18.
Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979–84.PubMedCrossRef
19.
Roth JA, Pass HI, Flanagan MM, Graeber GM, Rosenberg JC, Steinberg S. Randomized clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine, and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg. 1988;96(2):242–8.PubMed
20.
Siewert JR, Stein HJ, Feith M, Bruecher BL, Bartels H, Fink U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg. 2001;234(3):360–7; discussion 368–9.PubMedCrossRef
21.
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Walsh GL, et al. Comparison of clinical stage, therapy response, and patient outcome between squamous cell carcinoma and adenocarcinoma of the esophagus. Int J Gastrointest Cancer. 2005;36(2):69–76.PubMedCrossRef
22.
Kitajima M, Kitagawa Y. Surgical treatment of esophageal cancer—the advent of the era of individualization. N Engl J Med. 2002;347(21):1705–9.PubMedCrossRef
23.
Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47(1):207–14.PubMedCrossRef
24.
Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976;38(1):388–94.PubMedCrossRef
25.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L et al. New guidelines to evaluate the response to treatment in solid tumors European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRef
26.
James K, Eisenhauer E, Christian M, Terenziani M, Vena D, Muldal A et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst. 1999;91(6):523–8.PubMedCrossRef
27.
Brown WA, Thomas J, Gotley D, Burmeister BH, Lim KH, Martin I et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004;91(2):199–204.PubMedCrossRef
28.
Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle aspiration, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2005;129(6):1232–41.PubMedCrossRef
29.
Lightdale CJ, Kulkarni KG. Role of endoscopic ultrasonography in the staging and follow-up of esophageal cancer. J Clin Oncol. 2005;23(20):4483–9.PubMedCrossRef
30.
Griffith JF, Chan AC, Chow LT, Leung SF, Lam YH, Liang EY et al. Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT. Br J Radiol. 1999;72(859):678–84.PubMed
31.
Jones DR, Parker LA, Jr., Detterbeck FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer. 1999;85(5):1026–32.PubMedCrossRef
32.
Westerterp M, van Westreenen HL, Reitsma JB, Hoekstra OS, Stoker J, Fockens P et al. Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review. Radiology. 2005;236(3):841–51.PubMedCrossRef
33.
Ajani JA. Carcinoma of the esophagus: is biology screaming in my deaf ears? J Clin Oncol. 2005;23(19):4256–8.PubMedCrossRef
34.
Brücher BLDM, Stein HJ, Zimmermann F, Werner M, Sarbia M, Busch R et al. Responders benefit from neoadjuvant radiochemotherapy in esophageal squamous cell carcinoma: results of a prospective phase-II trial. Eur J Surg Oncol. 2004;30(9):963–71.PubMed
35.
Beer AJ, Wieder HA, Lordick F, Ott K, Fischer M, Becker K et al. Adenocarcinomas of esophagogastric junction: multi-detector row CT to evaluate early response to neoadjuvant chemotherapy. Radiology. 2006;239(2):472–80.PubMedCrossRef
36.
Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P et al. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg. 2007;84:393–400.PubMedCrossRef
37.
Goldstein EB (ed) Blackwell handbook of sensation and perception, 2nd edn. Oxford: Blackwell; 2005.
38.
Hayano K, Okazumi S, Shuto K, Matsubara H, Shimada H, Nabeya Y et al. Perfusion CT can predict the response to chemoradiation therapy and survival in esophageal squamous cell carcinoma: initial clinical results. Oncol Rep. 2007;18(4):901–8.PubMed
39.
Law S, Kwong DL, Wong KH, Kwok KF, Wong J. The effects of neoadjuvant chemoradiation on pTNM staging and its prognostic significance in esophageal cancer. J Gastrointest Surg. 2006;10(9):1301–11.PubMedCrossRef
40.
Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma Clinicopathologic correlations. Cancer. 1994;73(11):2680–6.PubMedCrossRef
41.
Salzer-Kuntschik M, Delling G, Beron G, Sigmund R. Morphological grades of regression in osteosarcoma after polychemotherapy—study COSS 80. J Cancer Res Clin Oncol. 1983;106(Suppl):21–4.PubMedCrossRef
42.
Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest. 2001;120(5):1584–91.PubMedCrossRef
43.
Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98(7):1521–30.PubMedCrossRef
44.
Brücher BLDM, Becker K, Lordick F, Fink U, Sarbia M, Stein H et al. The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas. Cancer. 2006;106(10):2119–27.PubMedCrossRef
45.
Schneider PM, Baldus SE, Metzger R, Kocher M, Bongartz R, Bollschweiler E et al. Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg. 2005;242(5):684–92.PubMedCrossRef
46.
Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R et al. Histologic subtypes as determinants of outcome in esophageal carcinoma patients with pathologic complete response after preoperative chemoradiotherapy. Cancer. 2006;106(3):552–8.PubMedCrossRef
47.
Brücher BLDM, Weber W, Bauer M, Fink U, Avril N, Stein HJ et al. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg. 2001;233(3):300–9.PubMedCrossRef
48.
Flamen P, van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G et al. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol. 2002;13(3):361–8.PubMedCrossRef
49.
Arslan L, Miller TR, Dehdashti F, Battafarano RJ, Siegel BA. Evaluation of response to neoadjuvant therapy by quantitative 2-deoxy–2-[18F]fluoro-D-glucose with positron emission tomography in patients with esophageal cancer. Mol Imaging. 2002;4(4):301–10.CrossRef
50.
Kroep JR, van Groeningen CJ, Cuesta MA, Craanen ME, Hoekstra OS, Comans EF et al. Positron emission tomography using 2-deoxy-2-[18F]fluoro-D-glucose for response monitoring in locally advanced gastrooesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol. 2003;5(5):337–46.PubMedCrossRef
51.
Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M et al. Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol. 2003;21(3):428–32.PubMedCrossRef
52.
Swisher S, Erasmus J, Masih M, Correa AM, Macapinlac H, Ajani JA et al. 2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004;101(8):1776–85.PubMedCrossRef
53.
Song JY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI et al. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys. 2005;63(4):1053–9.PubMed
54.
Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N et al. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg. 2002;184(3):279–83.PubMedCrossRef
55.
Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR et al. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg. 2006;243(4):472–8.PubMedCrossRef
56.
Duong CP, Hicks RJ. FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer. Eur J Nucl Med Mol Imaging. 2006;33(7):770–8.PubMedCrossRef
57.
Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI et al. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer. 2007;43(9):1385–91.PubMedCrossRef
58.
Konski AA, Cheng JD, Goldberg M, Li T, Maurer A, Yu JQ et al. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys. 2007;69(2):358–63.PubMed
59.
Ell PJ. The contribution of PET/CT to improved patient management. Br J Radiol. 2006;79(937):32–6.PubMedCrossRef
60.
Castell F, Cook GJR. Quantitative techniques in 18 FDG PET scanning in oncology. Br J Cancer. 2008;98:1597–1601.PubMedCrossRef
61.
Wong WL, Chamberas RJ. Role of PET/PET CT in staging and restaging of thoracic oesophageal cancer and gastro-oesophageal cancer: a literature review. Abdom Imaging. 2008;33:183–90.PubMedCrossRef
62.
Weber W, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19(12):3058–65.PubMed
63.
Wieder H, Brücher BLDM, Zimmermann F, Becker K, Lordick F, Beer A et al. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22(5):900–8.PubMedCrossRef
64.
Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24(29):4692–8.PubMedCrossRef
65.
Gillham CM, Lucey JA, Keogan M, Duffy GJ, Malik V, Raouf AA et al. (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer. 2006;95(9):1174–9.PubMedCrossRef
66.
Lordick F, Ott K, Krause B et al. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the Municon phase II trial. Lancet Oncol. 2007;46(6):263–70.
67.
Perez EA, Bawejy M. HER2-positive breast cancer: current treatment strategies. Cancer Invest. 2008;26(6):545–52.PubMedCrossRef
68.
Sarbia M, Pühringer-Oppermann F, Brücher BLDM. The predictive value of molecular markers (p53, EGFR, ATM, CHK2) in multimodal treated esophageal squamous cell carcinoma. Br J Cancer. 2007;97(19):1404–8.PubMedCrossRef
69.
Brücher BLDM, Keller G, Werner M, Müller U, Lassmann S, Cabras AD et al. Using Q-RT-PCR to measure Cyclin D1, TS, TP, DPD, and Her-2/neu as predictors for response, survival, and recurrence in patients with esophageal squamous cell carcinoma following radiochemotherapy. Int J Colorectal Dis. 2008;24(1):69–77.PubMedCrossRef
Metadaten
Titel
Response to Preoperative Therapy in Upper Gastrointestinal Cancers
verfasst von
Björn L. D. M. Brücher, MD, PhD, FACS
Stephen G. Swisher, MD, FACS
Alfred Königsrainer, MD
Derek Zieker, MD
Jörg Hartmann, MD
Hubert Stein, MD
Yuko Kitagawa, MD, FACS
Simon Law, MD, FACS, FRCS
Jaffer A. Ajani, MD
Publikationsdatum
01.04.2009
Verlag
Springer-Verlag
Erschienen in
Annals of Surgical Oncology / Ausgabe 4/2009
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0315-x

Weitere Artikel der Ausgabe 4/2009

Annals of Surgical Oncology 4/2009 Zur Ausgabe

Hepatobiliary and Pancreatic Tumors

Analysis of the Extent of Resection for Adenocarcinoma of the Gallbladder

Breast Oncology

Neoadjuvant Chemotherapy for Breast Cancer: Does Pretreatment Axillary Nodal Staging Improve Decision Making?

Breast Oncology

Endogenous NIS Expression in Triple-Negative Breast Cancers

Neuro-Oncology

Neurogenic Tumors of the Pelvis: Clinicopathologic Features and Surgical Outcomes Using a Multidisciplinary Team

Erratum

Detection and Functional Analysis of Tumor Infiltrating T-Lymphocytes (TIL) in Liver Metastases from Colorectal Cancer

Head and Neck Oncology

Impact of Hospital Volume on Surgical Outcome for Head and Neck Cancer

Neu im Fachgebiet Chirurgie

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Operationsvorbereitung | Nachrichten

Mehr Schaden als Nutzen durch präoperatives Aussetzen von GLP-1-Agonisten?

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Ureterstriktur: Innovative OP-Technik bewährt sich
weitere anzeigen

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Aktuelle BDC Leitlinien-Webinare

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.